Therapeutic Possibilities of Ceftazidime Nanoparticles in Devastating Pseudomonas Ophthalmic Infections; Keratitis and Endophthalmitis
Medical hypothesis discovery and innovation in ophthalmology,
Vol. 1 No. 1 (2012),
1 March 2012
,
Page 6-9
Abstract
As the number of contactâ€lens wearers rises worldwide, Pseudomonas aeruginosa (PA) keratitis is attracting more attention as a major public health issue. Corneal lesions of PA, being the most intimidating complication of contactâ€lens wearer, can progress rapidly in spite of local antibiotic treatment, and may result in perforation and the permanent loss of vision. One of the explanations proposed for the evasion of the pathogen from immune responses of the host as well as antibacterial treatment is the fact that invasive clinical isolates of PA have the unusual ability to invade and replicate within surface corneal epithelial cells. In this manner, PA is left with an intracellular sanctuary. Endophthalmitis, albeit rare, is another ophthalmic infection faced by the challenge of drug delivery that can be potentially catastrophic. The present hypothesis is that nanoparticles can carry antiâ€pseudomonas antibiotics (e.g. ceftazidime) through the membranes, into the “hidden zone†of the pathogen, hence being an effective and potent therapeutic approach against pseudomonas keratitis and endophthalmitis.
References
Forister JF, Forister EF, Yeung KK, Ye P, Chung MY, Tsui A, Weissman BA. Prevalence of contact lens-related complications: UCLA contact lens study. Eye Contact Lens. 2009 Jul;35(4):176-80. PMID: 19474751.
Cheng KH, Leung SL, Hoekman HW, Beekhuis WH, Mulder PG, Geerards AJ, Kijlstra A. Incidence of contact-lens-associated microbial keratitis and its related morbidity. Lancet. 1999 Jul 17;354(9174):181-5. PMID: 10421298.
Mohammadpour M, Mohajernezhadfard Z, Khodabande A, Vahedi P. Antibiotic susceptibility patterns of pseudomonas corneal ulcers in contact lens wearers. Middle East Afr J Ophthalmol. 2011 Jul;18(3):228-31. PMID: 21887079.
Zaidi T, Pier GB. Prophylactic and therapeutic efficacy of a fully human immunoglobulin G1 monoclonal antibody to Pseudomonas aeruginosa alginate in murine keratitis infection. Infect Immun. 2008 Oct;76(10):4720-5. PMID: 18644881.
Nejabat M, Masoumpour MB, Eghtedari M, Azarpira N, Ashraf MJ, Astane AR. Amniotic Membrane Transplantation for the Treatment of Pseudomonas Keratitis in Experimental Rabbits. Iranian Red Crescent Medical Journal. 2009 April;11(2):149-154.
Altan T, Acar N, Kapran Z, Unver YB, Yurttaser S, Küçüksümer Y, Eser I. Acute-onset endophthalmitis after cataract surgery: success of initial therapy, visual outcomes, and related factors. Retina. 2009 May;29(5):606-12. PMID: 19174718.
Baeyens V, Gurny R. Chemical and physical parameters of tears relevant for the design of ocular drug delivery formulations. Pharm Acta Helv. 1997 Sep;72(4):191-202. PMID: 9372641.
Kaur IP, Kanwar M. Ocular preparations: the formulation approach. Drug Dev Ind Pharm. 2002 May;28(5):473-93. PMID: 12098838.
Hämäläinen KM, Kananen K, Auriola S, Kontturi K, Urtti A. Characterization of paracellular and aqueous penetration routes in cornea, conjunctiva, and sclera. Invest Ophthalmol Vis Sci. 1997 Mar;38(3):627-34. PMID: 9071216.
Sasaki H, Yamamura K, Mukai T, Nishida K, Nakamura J, Nakashima M, Ichikawa M.Enhancement of ocular drug penetration. Crit Rev Ther Drug Carrier Syst.1999;16(1):85-146. PMID: 10099899.
Diebold Y, Calonge M. Applications of nanoparticles in ophthalmology. Prog Retin Eye Res. 2010 Nov;29(6):596-609. PMID: 20826225.
Keister JC, Cooper ER, Missel PJ, Lang JC, Hager DF. Limits on optimizing ocular drug delivery. J Pharm Sci. 1991 Jan;80(1):50-3. PMID: 2013850.
Yamamoto N, Yamamoto N, Petroll MW, Cavanagh HD, Jester JV. Internalization of Pseudomonas aeruginosa is mediated by lipid rafts in contact lens-wearing rabbit and cultured human corneal epithelial cells. Invest Ophthalmol Vis Sci. 2005 Apr;46(4):1348-55. PMID: 15790901.
Robertson DM, Petroll WM, Jester JV, Cavanagh HD. Current concepts: contact lens related Pseudomonas keratitis. Cont Lens Anterior Eye. 2007 May;30(2):94-107. PMID: 17084658.
Keck CM, Müller RH. Drug nanocrystals of poorly soluble drugs produced by high pressure homogenisation. Eur J Pharm Biopharm. 2006 Jan;62(1):3-16. PMID: 16129588.
Lallemand F, Felt-Baeyens O, Besseghir K, Behar-Cohen F, Gurny R. Cyclosporine A delivery to the eye: a pharmaceutical challenge. Eur J Pharm Biopharm. 2003 Nov;56(3):307-18. PMID: 14602172.
Kassem MA, Abdel Rahman AA, Ghorab MM, Ahmed MB, Khalil RM. Nanosuspension as an ophthalmic delivery system for certain glucocorticoid drugs. Int J Pharm. 2007 Aug 1;340(1-2):126-33. PMID: 17600645.
Calvo P, Alonso MJ, Vila-Jato JL, Robinson JR. Improved ocular bioavailability of indomethacin by novel ocular drug carriers. J Pharm Pharmacol. 1996 Nov;48(11):1147-52. PMID: 8961163.
Calvo P, Sanchez A, Martinez J, Lopez MI, Calonge M, Pastor JC, Alonso MJ. Polyester nanocapsules as new topical ocular delivery systems for cyclosporin A. Pharm Res. 1996 Feb;13(2):311-5. Erratum in: Pharm Res 1996 Sep;13(9):1423. PMID: 8932455.
Calvo P, Thomas C, Alonso M J, Vila-Jato J,Robinson JR. Study of the mechanism of interaction of poly (ϵ-caprolactone) nanocapsules with the cornea by confocal laser scanning microscopy. International journal of pharmaceutics. 1994;103(3):283-291.
Losa C, Calvo P, Castro E, Vila-Jato JL, Alonso MJ. Improvement of ocular penetration of amikacin sulphate by association to poly(butylcyanoacrylate) nanoparticles. J Pharm Pharmacol. 1991 Aug;43(8):548-52. PMID: 1681069.
Singh KH, Shinde UA. Development and Evaluation of Novel Polymeric Nanoparticles of Brimonidine Tartrate. Curr Drug Deliv. 2010 May 24. PMID: 20497099.
Chang SC, Lee MJ, Lin HM. Preparation of nano-and micrometric ceftazidime particles with supercritical anti-solvent technique. The Journal of Physical Chemistry C. 2008 Aug;112(38):14835-42.
Bu P, Riske PS, Zaya NE, Carey R, Bouchard CS. A comparison of topical chlorhexidine, ciprofloxacin, and fortified tobramycin/cefazolin in rabbit models of Staphylococcus and Pseudomonas keratitis. J Ocul Pharmacol Ther. 2007 Jun;23(3):213-20. PMID: 17593004.
McCormick C, Caballero A, Tang A, Balzli C, Song J, O'Callaghan R. Effectiveness of a new tobramycin (0.3%) and dexamethasone (0.05%) formulation in the treatment of experimental Pseudomonas keratitis. Curr Med Res Opin. 2008 Jun;24(6):1569-75. PMID: 18423106.
Onlen Y, Tamer C, Oksuz H, Duran N, Altug ME, Yakan S. Comparative trial of different anti-bacterial combinations with propolis and ciprofloxacin on Pseudomonas keratitis in rabbits. Microbiol Res. 2007;162(1):62-8. PMID: 16904302.
Ferrer C, RodrÃguez A, Abad JL, Fernandez J, Alió JL. Bactericidal effect of intravitreal levofloxacin in an experimental model of endophthalmitis. Br J Ophthalmol. 2008 May;92(5):678-82. PMID: 18211926.
- Abstract Viewed: 4984 times
- Full text PDF Downloaded: 3274 times
